Pulse Biosciences Inc. (NASDAQ: PLSE) announced it will redeem remaining warrants from its 2024 rights offering after meeting required stock price conditions. The company plans to deliver a redemption notice around June 10, 2026, for warrants that can be exercised until July 13, 2026, at $11.00 per share.

The redemption became possible after the company's volume weighted average price exceeded $22.00 per share for twenty consecutive trading days, with an average of $25.17 during that period. Warrants not exercised by the July deadline will be redeemed for $0.01 per warrant.

The bioelectric medicine company received $60 million from its July 2024 rights offering and has collected an additional $63.7 million from warrant exercises. If remaining warrants are exercised before redemption, the company expects another $2.1 million in proceeds.

Pulse Biosciences previously redeemed the first tranche of warrants from the rights offering in February 2025. The company develops nanosecond pulsed field ablation technology for medical applications including atrial fibrillation treatment.

The warrant redemption details were outlined in the company's Securities and Exchange Commission filings related to the 2024 rights offering, which was declared effective in May 2024.